Pacira BioSciences, Inc. (FRA:82P)
Germany · Delayed Price · Currency is EUR 16.80
-0.10 (-0.59%)
At close: Jan 30, 2026
Pacira BioSciences Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Net Income | 21.44 | -99.56 | 41.96 | 15.91 | 41.98 | 145.52 |
Depreciation & Amortization | 85.42 | 78.79 | 75.57 | 81 | 28.55 | 19.91 |
Other Amortization | 3.29 | 3.22 | 3.75 | 7.21 | 25.91 | 20.41 |
Loss (Gain) From Sale of Assets | - | - | - | - | - | 0.02 |
Asset Writedown & Restructuring Costs | 31.37 | 163.24 | - | 36.63 | - | - |
Loss (Gain) From Sale of Investments | 11 | - | - | 10 | - | -1.62 |
Stock-Based Compensation | 56.27 | 51.17 | 47.9 | 48.09 | 42.25 | 39.92 |
Other Operating Activities | 9.96 | 11.05 | 31.25 | -37.14 | 12.55 | -113.34 |
Change in Accounts Receivable | -14.59 | -7.75 | -7.16 | -2.08 | -10.43 | -5.52 |
Change in Inventory | -45.8 | -20.93 | -8.29 | 2.49 | -4.47 | -6.35 |
Change in Accounts Payable | -2.99 | 3.08 | 0.92 | 6.27 | -10.26 | -3.31 |
Change in Other Net Operating Assets | -13.92 | 7.07 | -31.24 | -23.11 | -0.35 | -18.61 |
Operating Cash Flow | 141.44 | 189.39 | 154.65 | 145.27 | 125.72 | 77.03 |
Operating Cash Flow Growth | -30.61% | 22.46% | 6.45% | 15.56% | 63.20% | 9.23% |
Capital Expenditures | -17.23 | -10.64 | -15.16 | -30.08 | -45.87 | -37.8 |
Cash Acquisitions | -16.7 | - | - | -32 | -424.04 | - |
Investment in Securities | 113.72 | -72.64 | 92.7 | -163.11 | 449.12 | -239.81 |
Investing Cash Flow | 79.78 | -83.28 | 77.54 | -225.19 | -20.79 | -277.61 |
Long-Term Debt Issued | - | 287.5 | 149.55 | - | 363.75 | 314.71 |
Long-Term Debt Repaid | - | -210.89 | -330.31 | -427.69 | - | -176.79 |
Net Debt Issued (Repaid) | -214.61 | 76.62 | -180.76 | -427.69 | 363.75 | 137.92 |
Issuance of Common Stock | 2.52 | 2.3 | 4.75 | 27.34 | 26.66 | 135.56 |
Repurchase of Common Stock | -105.63 | -25.49 | -0.11 | - | - | -33.09 |
Other Financing Activities | -2.2 | -36.06 | -6.91 | -1.18 | -9.71 | -18.08 |
Financing Cash Flow | -319.93 | 17.36 | -183.03 | -401.53 | 380.69 | 222.3 |
Net Cash Flow | -98.38 | 123.48 | 49.16 | -481.44 | 485.62 | 21.73 |
Free Cash Flow | 124.2 | 178.75 | 139.49 | 115.2 | 79.85 | 39.23 |
Free Cash Flow Growth | -35.82% | 28.15% | 21.09% | 44.27% | 103.54% | -35.01% |
Free Cash Flow Margin | 17.33% | 25.50% | 20.67% | 17.28% | 14.74% | 9.13% |
Free Cash Flow Per Share | 2.71 | 3.87 | 2.68 | 2.48 | 1.75 | 0.90 |
Cash Interest Paid | 15.62 | 15.42 | 27.64 | 33.3 | 7 | 7.21 |
Cash Income Tax Paid | 10.39 | 11.02 | 4.37 | 7.4 | 3.22 | 2.42 |
Levered Free Cash Flow | 78.4 | 163.38 | 107.15 | 92 | 49.79 | 38.75 |
Unlevered Free Cash Flow | 86.5 | 170.52 | 116.09 | 109.78 | 43.72 | 34.39 |
Change in Working Capital | -77.31 | -18.52 | -45.78 | -16.43 | -25.51 | -33.8 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.